Diabetes Devices Market Reports

Throughout this medical market research on the U.S. and European diabetes monitoring, treatment, and drug delivery markets, over 90 companies across 16 countries were analyzed. To conduct this research, our comprehensive methodology was utilized to understand the market sizes, unit sales, company market shares, and to create accurate forecasts. Previously, the U.S. diabetes monitoring, treatment, and

The U.S. and European insulin markets include long-acting insulin, ultra-long-acting insulin, rapid-acting insulin, premixed insulin, and human insulin. Within both the U.S. and the European markets the largest segment was the long-acting insulin market, which accounted for over 37% of the total market value. The long-acting insulin market has experienced increased competition, due to the expiration

The European diabetes monitoring, treatment, and drug delivery market, also referred to as the diabetes care market, includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pens, insulin syringes, and insulin pumps. Previously, the European diabetes monitoring, treatment, and drug-delivery market was valued at €6.8 billion.

The U.S. diabetes monitoring, treatment, and drug delivery market, also referred to as the diabetes care market, includes blood glucose meters, blood glucose test strips, lancets, continuous glucose monitoring (CGM), flash glucose monitoring (FGM), insulin, insulin pens, insulin syringes, and insulin pumps. Previously, the U.S. diabetes monitoring, treatment, and drug-delivery market was valued at $15.7

The U.S. and European insulin pump markets include durable pumps and patch pumps, which are further segmented to account for hardware and disposable components. Within both the U.S. and the European insulin pump markets, the largest segment was the durable pump market, which accounted for the majority of the total market value. Durable pumps account for

The full report suite on the U.S. market for diabetes monitoring, treatment and drug delivery includes blood glucose meters, blood glucose test strips, lancets and lancing devices, continuous glucose monitoring (CGM), insulin, inulin pens, insulin syringes and insulin pumps. Sanofi and Novo Nordisk recently launched next-generation insulin products: insulin glargine U-300 (Toujeo®) and insulin degludec (Tresiba®), respectively. Both of these insulin analogs are “ultra-long-acting” and have an average duration of 24 to 36 hours, which means that patients will only be required to perform once-daily injections. Novo Nordisk is currently developing Ryzodeg®, a premixed insulin analog comprising insulin degludec (Tresiba®) and insulin aspart (NovoLog®), in addition to an “ultra-rapid-acting” insulin analog, which are both expected to be launched during the forecast period. The insulin-dependent patient population is expected to transition to next-generation insulin products and will contribute to the growth of the insulin market and associated insulin delivery markets.